| 1. |
Lim LL, Jones S, Cikomola JC, et al. Understanding the drivers and consequences of early-onset type 2 diabetes[J]. Lancet, 2025, 405(10497): 2327-2340. DOI: 10.1016/S0140-6736(25)01012-8.
|
| 2. |
Ke D, Hong Y, Jiang X, et al. Clinical features and vitreous biomarkers of early-onset type 2 diabetes mellitus complicated with proliferative diabetic retinopathy[J]. Diabetes Metab Syndr Obes, 2022, 15: 1293-1303. DOI: 10.2147/DMSO.S362074.
|
| 3. |
Sattar N, Rawshani A, Franzén S, et al. Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks[J]. Circulation, 2019, 139(19): 2228-2237. DOI: 10.1161/CIRCULATIONAHA.118.037885.
|
| 4. |
Wang Y, Lin Z, Zhai G, et al. Prevalence of and risk factors for diabetic retinopathy and diabetic macular edema in patients with early- and late-onset diabetes mellitus[J]. Ophthalmic Res, 2022, 65(3): 293-299. DOI: 10.1159/000508335.
|
| 5. |
Okudaira M, Yokoyama H, Otani T, et al. Slightly elevated blood pressure as well as poor metabolic control are risk factors for the progression of retinopathy in early-onset Japanese type 2 diabetes[J]. J Diabetes Complications, 2000, 14(5): 281-287. DOI: 10.1016/s1056-8727(00)00114-8.
|
| 6. |
Fong DS, Ferris FL 3rd, Davis MD, et al. Causes of severe visual loss in the early treatment diabetic retinopathy study: ETDRS report no. 24. Early Treatment Diabetic Retinopathy Study Research Group[J]. Am J Ophthalmol, 1999, 127(2): 137-141. DOI: 10.1016/s0002-9394(98)00309-2.
|
| 7. |
Du X, Yang L, Kong L, et al. Metabolomics of various samples advancing biomarker discovery and pathogenesis elucidation for diabetic retinopathy[J/OL]. Front Endocrinol (Lausanne), 2022, 13: 1037164[2022-10-27]. https://pubmed.ncbi.nlm.nih.gov/36387907/. DOI: 10.3389/fendo.2022.1037164.
|
| 8. |
Kalyani RR, Neumiller JJ, Maruthur NM, et al. Diagnosis and treatment of type 2 diabetes in adults: a review[J]. JAMA, 2025, 334(11): 984-1002. DOI: 10.1001/jama.2025.5956.
|
| 9. |
Wilkinson CP, Ferris FL 3rd, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales[J]. Ophthalmology, 2003, 110(9): 1677-1682. DOI: 10.1016/S0161-6420(03)00475-5.
|
| 10. |
Skogvold HB, Sand ES, Elgst?en KBP. Global metabolomics using LC-MS for clinical applications[J]. Methods Mol Biol, 2025, 2855: 23-39. DOI: 10.1007/978-1-0716-4116-3_2.
|
| 11. |
Zhu XR, Yang FY, Lu J, et al. Plasma metabolomic profiling of proliferative diabetic retinopathy[J/OL]. Nutr Metab (Lond), 2019, 16: 37[2019-05-28]. https://pubmed.ncbi.nlm.nih.gov/31160916/. DOI: 10.1186/s12986-019-0358-3.
|
| 12. |
Munipally PK, Agraharm SG, Valavala VK, et al. Evaluation of indoleamine 2, 3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients[J]. Arch Physiol Biochem, 2011, 117(5): 254-258. DOI: 10.3109/13813455.2011.623705.
|
| 13. |
Kozie? K, Urbanska EM. Kynurenine pathway in diabetes mellitus-novel pharmacological target?[J/OL]. Cells, 2023, 12(3): 460[2023-01-31]. https://pubmed.ncbi.nlm.nih.gov/36766803/. DOI: 10.3390/cells12030460.
|
| 14. |
Lu Z, Zhang C, Zhang J, et al. The Kynurenine pathway and indole pathway in tryptophan metabolism influence tumor progression[J/OL]. Cancer Med, 2025, 14(6): e70703[2025-03-01]. https://pubmed.ncbi.nlm.nih.gov/40103267/. DOI: 10.1002/cam4.70703.
|
| 15. |
Zhang F, Guo R, Cui W, et al. Untargeted serum metabolomics and tryptophan metabolism profiling in type 2 diabetic patients with diabetic glomerulopathy[J]. Ren Fail, 2021, 43(1): 980-992. DOI: 10.1080/0886022X.2021.1937219.
|
| 16. |
Peck SC, Denger K, Burrichter A, et al. A glycyl radical enzyme enables hydrogen sulfide production by the human intestinal bacterium Bilophila wadsworthia[J]. Proc Natl Acad Sci USA, 2019, 116(8): 3171-3176. DOI: 10.1073/pnas.1815661116.
|
| 17. |
Das J, Roy A, Sil PC. Mechanism of the protective action of taurine in toxin and drug induced organ pathophysiology and diabetic complications: a review[J]. Food Funct, 2012, 3(12): 1251-1264. DOI: 10.1039/c2fo30117b.
|
| 18. |
Sak D, Erdenen F, Müderrisoglu C, et al. The relationship between plasma taurine levels and diabetic complications in patients with type 2 diabetes mellitus[J/OL]. Biomolecules, 2019, 9(3): 96[2019-03-11]. https://pubmed.ncbi.nlm.nih.gov/30862074/. DOI: 10.3390/biom9030096.
|
| 19. |
Güngel H, Erdenen F, Pasaoglu I, et al. New insights into diabetic and vision-threatening retinopathy: importance of plasma long pentraxine 3 and taurine levels[J]. Curr Eye Res, 2021, 46(6): 818-823. DOI: 10.1080/02713683.2020.1836228.
|
| 20. |
Fan Y, Lai J, Yuan Y, et al. Taurine protects retinal cells and improves synaptic connections in early diabetic rats[J]. Curr Eye Res, 2020, 45(1): 52-63. DOI: 10.1080/02713683.2019.1653927.
|